186 related articles for article (PubMed ID: 27899067)
1. Drug*placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design.
Hammami MM; Hammami S; Al-Swayeh R; Al-Gaai E; Farah FA; De Padua SJ
BMC Med Res Methodol; 2016 Nov; 16(1):166. PubMed ID: 27899067
[TBL] [Abstract][Full Text] [Related]
2. Short-term effects of morning versus evening dose of hydroxyzine 50 mg on cognition in healthy volunteers.
Conen S; Theunissen EL; Vermeeren A; Ramaekers JG
J Clin Psychopharmacol; 2011 Jun; 31(3):294-301. PubMed ID: 21508863
[TBL] [Abstract][Full Text] [Related]
3. A comparison of acrivastine versus hydroxyzine and placebo in the treatment of chronic idiopathic urticaria.
Salo OP; Harvey SG; Calthrop JG; Gibson JR
J Int Med Res; 1989; 17 Suppl 2():18B-21B. PubMed ID: 2569996
[TBL] [Abstract][Full Text] [Related]
4. Interaction between drug and placebo effects: a cross-over balanced placebo design trial.
Hammami MM; Al-Gaai EA; Alvi S; Hammami MB
Trials; 2010 Nov; 11():110. PubMed ID: 21092089
[TBL] [Abstract][Full Text] [Related]
5. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments.
García-Gea C; Martínez-Colomer J; Antonijoan RM; Valiente R; Barbanoj MJ
J Clin Psychopharmacol; 2008 Dec; 28(6):675-85. PubMed ID: 19011437
[TBL] [Abstract][Full Text] [Related]
6. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials.
García-Gea C; Martínez J; Ballester MR; Gich I; Valiente R; Antonijoan RM
Hum Psychopharmacol; 2014 Mar; 29(2):120-32. PubMed ID: 24395298
[TBL] [Abstract][Full Text] [Related]
7. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
8. A preliminary randomised double-blind placebo-controlled clinical trial of hydroxyzine for treating sleep bruxism in children.
Ghanizadeh A; Zare S
J Oral Rehabil; 2013 Jun; 40(6):413-7. PubMed ID: 23550945
[TBL] [Abstract][Full Text] [Related]
9. Acrivastine versus hydroxyzine in the treatment of cholinergic urticaria. A placebo-controlled study.
Kobza Black A; Aboobaker J; Gibson JR; Harvey SG; Marks P
Acta Derm Venereol; 1988; 68(6):541-4. PubMed ID: 2467496
[TBL] [Abstract][Full Text] [Related]
10. Objective antihistamine side effects are mitigated by evening dosing of hydroxyzine.
Goetz DW; Jacobson JM; Apaliski SJ; Repperger DW; Martin ME
Ann Allergy; 1991 Oct; 67(4):448-54. PubMed ID: 1683192
[TBL] [Abstract][Full Text] [Related]
11. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria.
Breneman DL
Ann Pharmacother; 1996 Oct; 30(10):1075-9. PubMed ID: 8893110
[TBL] [Abstract][Full Text] [Related]
12. Randomised controlled trials may underestimate drug effects: balanced placebo trial design.
Lund K; Vase L; Petersen GL; Jensen TS; Finnerup NB
PLoS One; 2014; 9(1):e84104. PubMed ID: 24416197
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyzine premedication--does it provide better anxiolysis than a placebo?
Boon JH; Hopkins D
S Afr Med J; 1996 Jun; 86(6):661-4. PubMed ID: 8764421
[TBL] [Abstract][Full Text] [Related]
14. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial.
Spahr L; Coeytaux A; Giostra E; Hadengue A; Annoni JM
Am J Gastroenterol; 2007 Apr; 102(4):744-53. PubMed ID: 17222324
[TBL] [Abstract][Full Text] [Related]
15. Does different information disclosure on placebo control affect blinding and trial outcomes? A case study of participant information leaflets of randomized placebo-controlled trials of acupuncture.
Cheon S; Park HJ; Chae Y; Lee H
BMC Med Res Methodol; 2018 Jan; 18(1):13. PubMed ID: 29347917
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
Barbanoj MJ; García-Gea C; Antonijoan R; Izquierdo I; Donado E; Pérez I; Solans A; Jané F
Hum Psychopharmacol; 2006 Jan; 21(1):13-26. PubMed ID: 16389668
[TBL] [Abstract][Full Text] [Related]
17. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers.
Barbanoj MJ; García-Gea C; Morte A; Izquierdo I; Pérez I; Jané F
Neuropsychobiology; 2004; 50(4):311-21. PubMed ID: 15539863
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
Lemoine P; Touchon J; Billardon M
Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
[TBL] [Abstract][Full Text] [Related]
19. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers.
Vuurman E; Theunissen E; van Oers A; van Leeuwen C; Jolles J
Hum Psychopharmacol; 2007 Jul; 22(5):289-97. PubMed ID: 17599335
[TBL] [Abstract][Full Text] [Related]
20. Controlled trial of H1 antagonists in the treatment of chronic idiopathic urticaria.
Sussman G; Jancelewicz Z
Ann Allergy; 1991 Oct; 67(4):433-9. PubMed ID: 1683191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
